Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
Sell
47
ATHE Quote, Financials, Valuation and Earnings
Last price:
$3.52
Seasonality move
:
5.7%
Day range:
$3.32 - $3.50
52-week range:
$1.00 - $5.87
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.46x
P/B ratio:
10.61x
Volume:
10.3K
Avg. volume:
18.3K
1-year change:
62.91%
Market cap:
$51.4M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingAlterity Therapeutics has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.00, Alterity Therapeutics has an estimated upside of 217% from its current price of $3.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $3.47.
Fair Value
-
According to the consensus of 2 analysts, Alterity Therapeutics has 217% upside to fair value with a price target of $11.00 per share.
ATHE vs. S&P 500
-
Over the past 5 trading days, Alterity Therapeutics has overperformed the S&P 500 by 8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Alterity Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alterity Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Alterity Therapeutics reported revenues of --.
Earnings Growth
-
Alterity Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Alterity Therapeutics reported earnings per share of --.
Enterprise value:
48.5M
EV / Invested capital:
--
Price / LTM sales:
2.46x
EV / EBIT:
--
EV / Revenue:
83.98x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2006-06-30 | 2007-06-30 | 2008-06-30 | 2007-06-30 | 2008-06-30 | |
| Income Statement | ||||||
| Revenue | $609.6K | $399.4K | $439.7K | $112.1K | $111.7K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$11.5M | -$12.1M | -$15.4M | -$9.4M | -$12.3M | |
| EBITDA | -$11.5M | -$12.1M | -$15.4M | -$9.4M | -$12.3M | |
| Diluted EPS | -$38.59 | -$37.23 | -$63.80 | -$5.13 | -$43.62 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $28.7M | $32.5M | $22.6M | -- | $6.5M | |
| Total Assets | $28.8M | $32.6M | $22.7M | -- | $6.6M | |
| Current Liabilities | $2.3M | $2.7M | $3.6M | -- | $1.7M | |
| Total Liabilities | $2.3M | $2.8M | $3.6M | -- | $1.7M | |
| Total Equity | $26.4M | $29.8M | $19.1M | -- | $4.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -$1.1K | -- | |
| Cash From Financing | -- | -- | -- | $695.2K | $241.9K | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
ATHE
Sector
Market Cap
$51.4M
$34.9M
Price % of 52-Week High
59.11%
42.85%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
62.91%
-40.42%
Beta (5-Year)
0.708
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.29
200-day SMA
Buy
Level
$2.33
Bollinger Bands (100)
Buy
Level
2.39 - 4.15
Chaikin Money Flow
Sell
Level
-486.6M
20-day SMA
Buy
Level
$3.20
Relative Strength Index (RSI14)
Buy
Level
54.01
ADX Line
Buy
Level
19.92
Williams %R
Sell
Level
-3.064
50-day SMA
Sell
Level
$3.67
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
1B
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
Stock Forecast FAQ
In the current month, ATHE has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ATHE average analyst price target in the past 3 months is $11.00.
-
Where Will Alterity Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alterity Therapeutics share price will rise to $11.00 per share over the next 12 months.
-
What Do Analysts Say About Alterity Therapeutics?
Analysts are divided on their view about Alterity Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alterity Therapeutics is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Alterity Therapeutics's Price Target?
The price target for Alterity Therapeutics over the next 1-year time period is forecast to be $11.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ATHE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alterity Therapeutics is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ATHE?
You can purchase shares of Alterity Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alterity Therapeutics shares.
-
What Is The Alterity Therapeutics Share Price Today?
Alterity Therapeutics was last trading at $3.52 per share. This represents the most recent stock quote for Alterity Therapeutics. Yesterday, Alterity Therapeutics closed at $3.47 per share.
-
How To Buy Alterity Therapeutics Stock Online?
In order to purchase Alterity Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
56
ROOT alert for Apr 23
Root [ROOT] is up 8.81% over the past day.
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 1.29% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is down 2.71% over the past day.
